

Rene Bruno

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7276335/rene-bruno-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

2,119
citations

22
h-index

45
g-index

67
ext. papers

2,418
ext. citations

4.2
avg, IF

4.35
L-index

#	Paper	IF	Citations
61	Clinical pharmacokinetics of bevacizumab in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 779-86	3.5	270
60	A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1996 , 24, 153-72		204
59	Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 56, 361-9	3.5	202
58	Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4103-8	2.2	170
57	Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 136-45	6.1	169
56	Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 792-801	2.9	156
55	Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2110-4	2.2	98
54	Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. <i>Investigational New Drugs</i> , 2001 , 19, 163-9	4.3	86
53	Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. <i>Clinical Cancer Research</i> , 2003 , 9, 1077-82	12.9	63
52	Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. <i>Statistics in Medicine</i> , 2002 , 21, 2623-39	2.3	61
51	Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 62, 518-26	6.1	54
50	Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 677-87	6.1	51
49	Evaluation of the linearity of docetaxel pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 42, 155-9	3.5	35
48	Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1985 , 13, 101-15		34
47	Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 1257-1267	3.5	33
46	Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3545-52	2.2	33
45	Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. <i>British Journal of Clinical Pharmacology</i> , 2003 , 56, 407-14	3.8	30

44	Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models. <i>Clinical Cancer Research</i> , 2020 , 26, 1787-1795	12.9	27
43	Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 1141-9	3.5	26
42	Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992 , 20, 653-69		24
41	Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 917-24	3.5	23
40	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. <i>Clinical Cancer Research</i> , 2018 , 24, 3292-3298	12.9	22
39	Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 1151-8	3.5	21
38	A modeling and simulation framework to support early clinical drug development decisions in oncology. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 6-8	2.9	19
37	Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 810-820	6.1	18
36	Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer 2019 , 7, 314		16
35	Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab. <i>Journal of Clinical Pharmacology</i> , 2014 , 54, 253-7	2.9	15
34	Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 567-73	3.5	14
33	A Model-Based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-Malignant Pain. <i>Pain and Therapy</i> , 2014 , 3, 31-44	3.6	13
32	Steady-state dosage regimen calculations in linear pharmacokinetics. <i>International Journal of Bio-medical Computing</i> , 1986 , 18, 167-82		13
31	Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra). <i>Pharmaceutical Research</i> , 2006 , 23, 1756-64	4.5	12
30	Dynamical dosage regimen calculations in linear pharmacokinetics. <i>Journal of Biomedical Informatics</i> , 1988 , 21, 203-20		10
29	Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 956-958	6.1	10
28	Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response. <i>Blood</i> , 2011 , 118, 1881-1881	2.2	9
27	Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 49-54	3.5	8

26	Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors. <i>Anti-Cancer Drugs</i> , 1999 , 10, 889-94	2.4	8
25	Methotrexate and 7-hydroxy-methotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 1385-90		8
24	Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAB) in the Second- and Third-Line Non-Small Cell Lung Cancer. <i>AAPS Journal</i> , 2017 , 19, 527-533	3.7	6
23	Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020 , 47, 613-625	2.7	5
22	Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 605-10	3.5	5
21	Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 1042-1052	2.9	4
20	Time-dependent population PK models of single-agent atezolizumab in patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 88, 211-221	3.5	3
19	Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation. <i>BMC Cancer</i> , 2016 , 16, 473	4.8	3
18	Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1). <i>Clinical and Translational Science</i> , 2021 ,	4.9	3
17	Tumor Time-Course Predicts Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow-Up Time. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020 , 9, 115-123	4.5	2
16	Reply to U.R. Mansmann et al and M.-W. An et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4374-5	2.2	2
15	Model-based estimates of tumor growth inhibition (TGI) metrics to predict for overall survival (OS) in first-line non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, e19049-e19049	2.2	2
14	A tumor growth rate/overall survival model for atezolizumab as an early predictor of OS in patients with first or second line metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 62-62	2.2	2
13	Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. <i>Liver Cancer</i> , 2021 , 10, 485-499	9.1	2
12	Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 930-933	4.3	2
11	Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2493-2501	3.8	2
10	Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 1171-1182	4.5	2
9	Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). <i>Clinical and Translational Science</i> , 2021 ,	4.9	2

8	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Response. <i>Clinical Cancer Research</i> , 2020 , 26, 2436	12.9	1
7	Bayesian inference using Hamiltonian Monte-Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy. <i>Statistics in Medicine</i> , 2020 , 39, 4853-4868	2.3	1
6	Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden. <i>Pharmacology Research and Perspectives</i> , 2020 , 8, e00685	3.1	1
5	Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 1255-1266	4.5	1
4	Application of Machine Learning for Tumor Growth Inhibition - Overall Survival Modeling Platform. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 59-66	4.5	1
3	Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to Mistry. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017 , 6, 225	4.5	
2	Letter to the editor: Model-based simulation to support the extended dosing regimens of atezolizumab. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 1065-1066	2.8	
1	Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study.. <i>AAPS Journal</i> , 2022 , 24, 58	3.7	